Insight Molecular Diagnostics Inc. (IMDX)

Market Cap	90.37M
Revenue (ttm)	3.84M
Net Income (ttm)	-58.26M
Shares Out	28.60M
EPS (ttm)	-3.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,462,410
Open	3.040
Previous Close	3.200
Day's Range	2.760 - 3.230
52-Week Range	1.922 - 4.750
Beta	0.99
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2025

About IMDX

OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monito...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: IMDX
• Website: https://www.oncocyte.com

Financial Performance

In 2024, IMDX's revenue was $1.88 million, an increase of 25.15% compared to the previous year's $1.50 million. Losses were -$60.93 million, 112.1% more than in 2023.